This content is only available within our institutional offering.
04 Nov 2019
BAYER: Is Xarelto protected from generics after 2024 in the EU too? | SELL | EUR64(-8%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
BAYER: Is Xarelto protected from generics after 2024 in the EU too? | SELL | EUR64(-8%)
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
04 Nov 2019 -
Author:
Jean-Jacques Le Fur -
Pages:
4
BAYER - SELL | EUR64(-8%)
Is Xarelto protected from generics after 2024 in the EU too?
Settlement between Bayer/J&J and Mylan
What is the context?
The most important is Europe for Bayer